20/20 Biolabs, Inc. (AIDX) income statement
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19−0.00 (-1.01%)
Close on Nov 18, 2026Market cap $2.37MP/E –Yield –
20/20 Biolabs, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- 29.6%
- Operating margin
- -162.9%
- Net margin
- -182.8%
- Return on equity, FY2025
- -503.1%
Financial strength
- Current ratio
- 1.99
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 178.2%
Valuation
- P/E ratio
- –
- Price to sales
- 1.16
- Price to book
- 1.46
- Dividend yield
- –
See a number that looks wrong?